Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter Inks Licensing Deal with INSERM for ValidPrime Technology

NEW YORK (GenomeWeb) – Tataa Biocenter today announced it has signed an exclusive agreement to license the French Institute for Health and Medical Research's (INSERM) ValidPrime qPCR assay correction technology.

ValidPrime is a tool used to measure and compensate for the genomic DNA background signal in qPCR-based gene expression measurements. The technology "accurately corrects all reactions in high-throughput qPCR BioMark arrays for signals derived from gDNA," Vlasta Korenkova, head of Tataa's Prague facility, said in a statement.

ValidPrime is an alternative to performing extra control measurements needed to eliminate the gDNA background noise, and "in our high-throughput measurements, we save up to 95 percent of reagent cost and data are of excellent quality," Korenkova said.

ValidPrime is also used to standardize analyses of cell-free DNA, Göteborg, Sweden-based Tataa, a genomic services firm, said.

Financial and other terms of the agreement were not disclosed. 

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.